PRVB News and Press, Provention Bio Inc. From 12/05/22

Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence . The pharmaceutical company closed out October at $6.94 and opened November at $7. It rose to a 52-week high of $9.85 on Nov. 25 and closed out the month at $9.04. Its s...

Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Ad...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Zigres / Shutterstock.com Tesla (NASDAQ: TSLA ) stock is in the news Friday as investors react to the electric vehicle company (EV) recalling 30,000 Model X units . The recall of these EVs has to do w...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Tinseltown / Shutterstock Ticketmaster, which is owned by Live Nation Entertainment (NYSE: LYV ), is caught up in drama after it had to cancel sales of Taylor Swift tickets. The controversy started on...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s a good-news, bad-news situation happening with Provention Bio (NASDAQ: PRVB ) today. Provention’s management is celebrating a watershed moment with a Food and Drug Administration (FDA) approval of ...

TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D PR Newswire TZIELD is the first disease-modifying ther...

Provention Bio, Inc. (PRVB) Q3 2022 Results Conference Call November 03, 2022 08:00 AM ET Company Participants Heidy King-Jones - Chief Legal Officer Ashleigh Palmer - CEO and Co-Founder Jason Hoitt - Chief Commercial Officer Thierry Chauche - CFO Confe...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It may be a mixed session for the overall market on Thursday, but not for Provention Biosciences (NASDAQ: PRVB ). That’s as PRVB stock is up 25% so far in the session and hitting its highest level since July 20...

Provention Bio, Inc. ( NASDAQ: PRVB ) added ~27% intraday Thursday after the clinical-stage biopharma announced with its Q3 2022 results that the FDA issued its proposed labeling for the experimental diabetes therapy teplizumab. An anti-CD3 monoclonal antibody, tep...

Provention Bio press release ( NASDAQ: PRVB ): Q3 GAAP EPS of -$0.34 beats by $0.08 . Revenue of $0.8M (+17.6% Y/Y) beats by $0.02M . Cash-based operating expenses for the third quarter of 2022 were $26.4M, which exclude non-cash, stock-based compensation expen...